Suppr超能文献

艰难梭菌感染:流行病学、发病机制、危险因素及治疗选择

Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options.

作者信息

Goudarzi Mehdi, Seyedjavadi Sima Sadat, Goudarzi Hossein, Mehdizadeh Aghdam Elnaz, Nazeri Saeed

机构信息

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran.

Department of Pharmaceutical Biotechnology, Pasteur Institute of Iran (IPI), No. 358, 12th Farwardin Avenue, Jomhhoori Street, Tehran 1316943551, Iran.

出版信息

Scientifica (Cairo). 2014;2014:916826. doi: 10.1155/2014/916826. Epub 2014 Jun 1.

Abstract

The incidence and mortality rate of Clostridium difficile infection have increased remarkably in both hospital and community settings during the last two decades. The growth of infection may be caused by multiple factors including inappropriate antibiotic usage, poor standards of environmental cleanliness, changes in infection control practices, large outbreaks of C. difficile infection in hospitals, alteration of circulating strains of C. difficile, and spread of hypervirulent strains. Detection of high-risk populations could be helpful for prompt diagnosis and consequent treatment of patients suffering from C. difficile infection. Metronidazole and oral vancomycin are recommended antibiotics for the treatment of initial infection. Current treatments for C. difficile infection consist of supportive care, discontinuing the unnecessary antibiotic, and specific antimicrobial therapy. Moreover, novel approaches include fidaxomicin therapy, monoclonal antibodies, and fecal microbiota transplantation mediated therapy. Fecal microbiota transplantation has shown relevant efficacy to overcome C. difficile infection and reduce its recurrence.

摘要

在过去二十年中,艰难梭菌感染的发病率和死亡率在医院和社区环境中均显著上升。感染的增加可能由多种因素引起,包括抗生素使用不当、环境卫生标准差、感染控制措施的变化、医院内艰难梭菌感染的大规模暴发、艰难梭菌流行菌株的改变以及高毒力菌株的传播。检测高危人群有助于对艰难梭菌感染患者进行及时诊断和后续治疗。甲硝唑和口服万古霉素是治疗初始感染的推荐抗生素。目前艰难梭菌感染的治疗包括支持治疗、停用不必要的抗生素以及特异性抗菌治疗。此外,新的治疗方法包括非达霉素治疗、单克隆抗体和粪便微生物群移植介导的治疗。粪便微生物群移植已显示出克服艰难梭菌感染并降低其复发率的相关疗效。

相似文献

1
Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options.
Scientifica (Cairo). 2014;2014:916826. doi: 10.1155/2014/916826. Epub 2014 Jun 1.
2
[Individualized treatment strategies for Clostridium difficile infections].
Internist (Berl). 2017 Jul;58(7):675-681. doi: 10.1007/s00108-017-0268-2.
3
Clostridium difficile infection in older adults: a review and update on its management.
Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20.
4
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Cochrane Database Syst Rev. 2011 Sep 7(9):CD004610. doi: 10.1002/14651858.CD004610.pub4.
5
Update of treatment algorithms for Clostridium difficile infection.
Clin Microbiol Infect. 2018 May;24(5):452-462. doi: 10.1016/j.cmi.2017.12.022. Epub 2018 Jan 6.
6
Emerging drugs for the treatment of clostridium difficile.
Expert Opin Emerg Drugs. 2019 Mar;24(1):17-28. doi: 10.1080/14728214.2019.1591371. Epub 2019 Mar 20.
7
Clostridium difficile infection: A brief update on emerging therapies.
Am J Health Syst Pharm. 2015 Jun 15;72(12):1007-12. doi: 10.2146/ajhp140645.
8
Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1239-1250. doi: 10.1080/17512433.2017.1362978. Epub 2017 Aug 11.
9
My Treatment Approach to Clostridioides difficile Infection.
Mayo Clin Proc. 2021 Aug;96(8):2192-2204. doi: 10.1016/j.mayocp.2021.03.033. Epub 2021 Jun 24.
10
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.
Curr Opin Gastroenterol. 2012 Jan;28(1):1-9. doi: 10.1097/MOG.0b013e32834bc9a9.

引用本文的文献

1
Multi-epitope vaccine design against using the ABC-type transport system protein.
Bioinformation. 2025 May 31;21(5):990-996. doi: 10.6026/973206300210990. eCollection 2025.
5
Gut Microbiota and New Microbiome-Targeted Drugs for Infections.
Antibiotics (Basel). 2024 Oct 20;13(10):995. doi: 10.3390/antibiotics13100995.
6
Therapeutics involved in managing initial and recurrent infection: An updated literature review.
World J Gastrointest Pharmacol Ther. 2024 Sep 5;15(5):95467. doi: 10.4292/wjgpt.v15.i5.95467.
7
Current and Ongoing Developments in Targeting Infection and Recurrence.
Microorganisms. 2024 Jun 15;12(6):1206. doi: 10.3390/microorganisms12061206.
10
Infection in Hospitalized Patients-A Retrospective Epidemiological Study.
Healthcare (Basel). 2023 Dec 29;12(1):76. doi: 10.3390/healthcare12010076.

本文引用的文献

1
Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.
Iran Red Crescent Med J. 2013 Aug;15(8):704-11. doi: 10.5812/ircmj.5189. Epub 2013 Aug 5.
2
Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review.
Tech Coloproctol. 2014 Mar;18(3):223-32. doi: 10.1007/s10151-013-1081-0. Epub 2013 Nov 1.
3
Epidemiology of Clostridium difficile infection in Asia.
Antimicrob Resist Infect Control. 2013 Jul 1;2(1):21. doi: 10.1186/2047-2994-2-21.
4
Clostridium difficile Infection.
Med Clin North Am. 2013 Jul;97(4):523-36, ix. doi: 10.1016/j.mcna.2013.02.003. Epub 2013 Apr 24.
5
Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.
Ann Intern Med. 2012 Dec 18;157(12):878-88. doi: 10.7326/0003-4819-157-12-201212180-00563.
6
Clostridium difficile infection: new insights into management.
Mayo Clin Proc. 2012 Nov;87(11):1106-17. doi: 10.1016/j.mayocp.2012.07.016.
7
Hospital-acquired Clostridium difficile infection: determinants for severe disease.
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1923-30. doi: 10.1007/s10096-011-1522-5. Epub 2011 Dec 31.
9
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.
Curr Opin Gastroenterol. 2012 Jan;28(1):1-9. doi: 10.1097/MOG.0b013e32834bc9a9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验